Replace Animal Tests Act of 2025
- Sponsor
- Rep. Moskowitz, Jared [D-FL-23]
- Committees
- Agriculture Committee (primary)
- Last action
- Jan 13, 2026
Bottom line
The bill aims to significantly reduce and eventually replace animal testing for regulatory purposes across several key federal agencies by prioritizing and mandating the use of non-animal methods.
What it actually does
This bill prohibits entities from submitting data derived from animal testing to specified federal agencies (CPSC, USDA, EPA, FDA) if a scientifically satisfactory non-animal test method is available and accepted, or if a waiver has been issued. It mandates these agencies to issue guidance, revise regulations, and publish annual reports on the use of non-animal methods, while also establishing penalties for non-compliance and requiring humane practices when animal testing is still necessary.
Proponents argue
Supporters argue that this legislation is a crucial step towards modernizing regulatory science, promoting ethical treatment of animals, and encouraging the development and adoption of more humane, efficient, and potentially more human-relevant non-animal testing methods, aligning the U.S. with global trends in animal welfare and scientific innovation.
Opponents contend
Opponents might express concerns that the bill could lead to premature restrictions on animal testing in areas where non-animal methods are not yet fully validated or accepted for all complex safety endpoints, potentially causing delays in product approvals or compromising public safety and environmental protection, while also imposing significant adaptation costs on regulated industries.
The bill is concise and clearly written, making it accessible for a quick read and allowing ample time for stakeholders to understand its core implications.
Section 2(a)
Mandatory Use of Non-Animal Test Methods
This provision makes it unlawful for any entity to submit data derived from animal testing to a covered federal agency if a scientifically satisfactory non-animal test method is available and accepted by that agency, or if the agency has granted a waiver. This fundamentally shifts the regulatory default from animal testing to non-animal alternatives, requiring industries to prioritize and utilize modern non-animal approaches whenever feasible for product and substance evaluations.
Supporters argue
Supporters argue this provision is essential for advancing animal welfare by directly reducing the demand for animal testing and for fostering scientific innovation in the development and adoption of more humane and potentially more predictive non-animal testing methods.
Critics contend
Some industry groups might argue that this provision could prematurely restrict the use of animal testing in cases where non-animal methods are not yet fully validated or accepted for all complex endpoints, potentially hindering product development or safety assessments.
Tradeoffs
This provision balances the ethical imperative to reduce animal suffering with the practical need for robust and scientifically sound data to ensure product safety and efficacy.
Section 2(b)
Exceptions to the Prohibition on Animal Testing Data
The bill outlines specific circumstances under which animal test data can still be submitted to covered agencies. These exceptions include data generated before the bill's enactment, data required by foreign regulatory authorities, data requested by an agency due to insufficient existing data and the unavailability of scientifically satisfactory non-animal methods, and data from specific animal tests explicitly requested in writing by an agency with clear justification.
Section 2(c)
Minimizing Animal Use and Suffering in Permitted Tests
In cases where no appropriate non-animal test method is available and a waiver has not been granted, meaning animal testing is still permitted, regulated entities are mandated to ensure that the number of animals used is reduced to the minimum possible without compromising the test objectives. Furthermore, they must reduce to a minimum any possible pain, suffering, distress, or lasting harm to the animals used, aligning with the ethical principles of reduction and refinement.
Section 2(d)
Enforcement and Civil Penalties for Non-Compliance
This section grants covered agencies the authority to refuse to accept animal testing data that has been generated in violation of the Act. Additionally, agencies are empowered to impose civil penalties of up to $10,000 for each violation on any person who fails to comply with the bill's requirements. These measures provide a clear and direct enforcement mechanism to ensure adherence to the new non-animal testing mandates.
Section 2(e)
Agency Guidance and Regulatory Revisions
Within one year of the bill's enactment, each covered agency is mandated to issue guidance on the acceptability and use of non-animal test methods for products and substances they regulate. Furthermore, agencies are directed to revise their existing regulations to reflect the acceptability of these non-animal methods and, where appropriate, eliminate requirements for corresponding animal test data. This ensures a structured and clear transition for industries.
Section 2(f)
Annual Public Reporting on Animal and Non-Animal Testing
Starting one year after enactment, each covered agency must annually publish a progress report detailing the use of non-animal test methods by the agency and its regulated entities. These reports must specify the number and species of animals used, the types of testing conducted, the number of waivers issued, and the purpose of all test methods and waivers. This information must be made publicly available on the agency's website, with personally identifiable and proprietary information omitted.
Defines the term "animal" for the purposes of this Act as "a live vertebrate non-human animal or cephalopod."
Section 2(g)(1)
Why it matters:This is standard legislative practice to consolidate definitions in a dedicated section, ensuring clarity and consistency throughout the text.
Case for: Supporters would argue that this definition provides essential clarity and expands the scope of protection beyond traditional vertebrates to include cephalopods, which are increasingly recognized for their complex nervous systems and capacity for sentience, aligning the bill with evolving scientific understanding and ethical considerations.
Case against: Some might argue that including cephalopods expands the scope of the bill beyond what is typically considered 'animal testing' in some contexts, potentially increasing the regulatory burden on specific industries that use these organisms in research or testing, without sufficient prior public debate.
Estimated impact: Broadens the scope of animal welfare protections under this Act to include a specific group of invertebrates, impacting industries that use cephalopods in research or testing.
Specifies the "covered agencies" subject to the bill's requirements: the Consumer Product Safety Commission (CPSC), the Department of Agriculture (USDA), the Environmental Protection Agency (EPA), and the Food and Drug Administration (FDA).
Section 2(g)(3)
Why it matters:This is standard legislative practice to define the scope of application within a dedicated definitions section, ensuring precision and avoiding repetition in the main text.
Case for: Supporters would argue that these agencies are the primary federal regulators for products and substances that commonly involve animal testing, making them the most appropriate and impactful targets for this legislation to achieve its goals of reducing animal use.
Case against: Critics might argue that other federal agencies (e.g., Department of Defense for certain research, National Institutes of Health for grant-funded research) also conduct or require animal testing and are excluded from this bill, potentially limiting its overall impact on animal welfare across the federal government.
Estimated impact: This definition is foundational, as it precisely delineates which federal regulatory bodies, and by extension, which industries, will be directly impacted by the bill's mandates.